Dans un contexte où les stratégies de croissance transatlantiques occupent une place centrale dans le développement des entreprises de santé innovantes, France Biotech organise en partenariat avec DLA Piper, membre de l’association, l’événement : « France–US Crossed-Views : Life Sciences Growth and Investment Strategies »
🗓️ Jeudi 22 mai 2025, à partir de 14h30
📍 DLA Piper France – 27 rue Laffitte, 75009 Paris
Cet après-midi d’échanges, en présence notamment de Frédéric Girard, président de France Biotech, réunira des experts de l’écosystème biopharma, medtech et techbio pour débattre des défis et des opportunités en matière de financement, licensing, fusions-acquisitions et régulation, en France comme aux États-Unis. Des intervenants de premier plan – dirigeants d’entreprises innovantes, investisseurs, et spécialistes juridiques – partageront leurs retours d’expérience et apporteront des perspectives concrètes pour accompagner votre développement à l’international.
👉 Je m’inscris >>ici<<
👉 Découvrez le programme :
|
|
Introduction
- Sonia de Kondserovsky (Partner, Head of Life Sciences, DLA Piper France),
- Frédéric Girard (President, France Biotech).
|
|
|
|
Panel 1: Raising capital in France and in the US
- Raising private capital,
- Royalty financing,
- Raising capital on the financial markets (double listings Euronext/ Nasdaq).
Moderator: Victoria Rhodes (Partner, DLA Piper UK).
DLA Piper speakers:
- Joshua Kaufman (Co-Chair Capital Markets, DLA Piper US) – Listings and dual listings,
- Shehzad Huda (Emerging Growth and Venture Capital, DLA Piper US) – Private capital raisings.
External experts:
- Renée Aguiar-Lucander, (CEO, Hansa Biopharma and former CEO, Calliditas Therapeutics AB).
- Pascal Caisey (Chief Operating Officer, Genfit),
- Vincent Meunier (Healthcare Investment Banking MD, Bryan Garnier),
- Asnen Cassam-Chenai (Director of Healthcare, Eurazeo).
[Names of Bpifrance and US fund representatives to be specified].
|
|
|
|
Panel 2: Licensing and M&A trends
- Comparing ecosystems and market dynamics,
- Strategic tips for licensing and M&A.
Moderator: Sonia de Kondserovsky (Partner, Head of Life Sciences, DLA Piper France).
DLA Piper speakers:
- Lauren Murdza (Co-Chair Life Sciences Licensing and Commercial Transactions, DLA Piper US. Represented Pfizer in its licensing transaction with BioNtech re. Covid-19 vaccine).
External experts:
- Philippe Lopes Fernandes (Executive Vice President, Chief Business Officer, Ipsen),
- Frédéric Scaerou (Head of Global Business Development, Servier),
- Michael Stewart (Global Head of Legal Transactions, Sanofi).
- Nicolas Poirier (CEO, OSE Immunotherapeutics),
- Robert Rozemulder (Managing Director, Rothschild).
|
|
|
|
Panel 3: Solving the regulatory puzzle: AI, Data, and Products Regulations
- Navigating the increasingly complex regulatory landscape,
- Impact of the latest reforms,
- Key take-aways from experts and industry players.
Moderator: Marco de Morpurgo (Partner, Global Co-Chair, Life Sciences Sector, DLA Piper Europe).
DLA Piper speakers:
- Denise Lebeau-Marianna (Partner Data Privacy, Head of IPT, DLA Piper France),
- Marion Abecassis (Senior Associate, Life Sciences & Regulatory, DLA Piper France).
External experts:
- David Del Bourgo (CEO and Co-founder, WhiteLab Genomics – Leader of the TechBio initiative at France Biotech),
- Simon Turner (Partner in Digital Medicine strategy, Sofinnova),
- Arnaud Rosier (CEO and Co-founder, Implicity).
|
|
